InvestorsHub Logo
Followers 1
Posts 307
Boards Moderated 0
Alias Born 07/24/2015

Re: None

Thursday, 04/02/2020 2:29:47 AM

Thursday, April 02, 2020 2:29:47 AM

Post# of 429479
Found a case with notable similarities to our circumstances:

https://www.finnegan.com/en/tools/in-re-cyclobenzaprine-hydrochlorine-extended-release-capsule/analysis.html

What’s particularly incredible to me is that the specific error mentioned in the Sherkow call today, burden-shifting when evaluating secondary considerations of obviousness, is explicitly mentioned in Judge Du’s pretrial order.

Google: amrn iHub cyclobenzaprine and you’ll find marjacs post and go to paragraph 234. In that paragraph it clearly cites the federal circuits rationale for overturning a district judges error for using the same erroneous methodology that Judge Du employed
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News